Disclaimer

The ideas, views and opinions expressed in here in blog or comments and profile represent my own views and not those of any of my current or previous employer .They are based and taken from regulatory guidance available freely and my interpretations from my experience.

Saturday, 20 January 2024

Summary of Module X – Additional monitoring

Module X – Additional monitoring

Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module VI having covered module I , II, III, IV, V, VI VII and IX in previous blogs.

This module describes the requirements for medicinal products that are subject to additional monitoring.

These medicinal products will be readily identifiable by an inverted equilateral black triangle as stipulated in the Implementing Regulation (EU) No 198/2013. 

That triangle will be followed by an explanatory statement in the summary of product characteristics (SmPC) as follows: “This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.”

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to participate, perform and/or review such products.

Reference:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf

1. Why additional monitoring is needed?

For products whose safety profile is not established, collection of ADR remains primary source to know risk profile of product. Additional monitoring will enhance the reporting, collection and analysis of adverse event data to establish so.

2. When is additional monitoring is requested?

Agency /NCA at the time of granting marketing authorization. Later in lifecycle of product when any new risk emerges and this requires additional monitoring. Usually for new active ingredient, biological product and products that require PASS. Detailed guidance on which product mandatorily require additional monitoring and which are optional are mentioned in module. Usually once the product is included in the list, it will be for 5 years. unless otherwise specified by Agency in consultation with PRAC.

3. How is it done?

Agency/NCA will publish the list of medicinal products that require additional monitoring. PRAC recommendation is also taken especially in optional situations. MAH is required to maintain the black triangle warning on their SmPC. MAH will then continue to monitor this products and any change is notified to NAC/AGENCY for further actions/confirmation.

This module helps understand the requirements of additional monitoring.

Written by:

Dr.Shraddha Bhange.

Connect with me Via comments below. (I do not respond to Facebook or Linkedin messages actively)

Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home

Summary of Module IX – Signal management

 

 Summary of Module IX – Signal management


Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module VI having covered module I , II, III, IV, V, VI and VII in previous blogs.

This module describes the signal requirements.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to participate, perform and/or review signals.

Reference:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf


Signal: Information arising from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action.For the purpose of monitoring data in EudraVigilance, only signals related to an adverse reaction shall be considered.

Sources: Sources may include spontaneous reports, clinical studies and the scientific literature.

A signal generally involves an active substance regardless of its indication, strength or route of administration and applies to all brand names / medicinal products containing the active substance, including fixed combinations. However, in some instances a signal may be relevant only to a particular indication, strength or route of administration. On the other hand, a signal may encompass all active substances of a therapeutic class.

Process:

  • Steps in signal management are detection, validation, confirmation and prioritization. Prioritization is throughout the lifecycle. 

Timelines:

  • Emerging safety issue: as soon as possible but no later than 3 days
  • Monitoring of EudraVigilance data at least every 6 months unless requested otherwise or the product is part of monitoring list.
  • Standalone signal notification: This should be done as soon as possible and no later than 30 days after the marketing authorization holder has completed their assessment and concluded that further analysis by the competent authorities is required.

Expectations from MAH:

  •  All organizations should have a robust signal management process and keep an audit trail of their signal management activities, allowing traceability and process control of all steps of signal management, including analyses, decisions and rationale for all the sources, methods and outcome of signals.
  • In EU Signal management is required for list of active substances as published on EMA website.
  • Refuted signals should only be reported in PSURs. Other validated signals should be reported as standalone notification, through submission of safety variations and/or within PSURs. Validated signals should also be presented in the relevant sections of the periodic safety update report (PSUR).
  • Standalone notifications of signals detected in EudraVigilance within the scope of the pilot should be sent to the Agency (MAH-EV-signals@ema.europa.eu) and to the competent authorities member States where the medicinal product is authorized. The standalone signal notification form and the national contact points are available on the EMA signal management webpage.
  • MAHs have a legal obligation to ensure that their product information is kept up to date with the current scientific knowledge, including published PRAC recommendations on signals
  • If the MAH considers that a validated signal from any source may qualify as an Emerging Safety Issue, they should notify it in writing to the competent authorities in Member States where the medicinal product is authorized and to the EMA via email (P-PV-emerging-safety-issue@ema.europa.eu), as per the process outlined in GVP Module IX.
  • Various components on where to report what type of signal in what timelines are detailed in the module.  The details regarding how to scientifically validate, confirm or prioritize signals is also provided.



Written by:

Dr.Shraddha Bhange.

Connect with me Via comments below. (I do not respond to Facebook or Linkedin messages actively)

Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home

Summary of Module VII – Periodic safety update report

 Summary of Module VII – Periodic safety update report


Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module VI having covered module I , II, III, IV, V and VI in previous blogs.

This module describes the PSUR requirements.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to write, compile, review or submit PSUR.

Reference:https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf

What is PSUR?

It is legally required document for a medicinal product that needs to be submitted by MAH to agency and/or national competent authority after the drug is approved at a set frequency within defined timelines.

The format and content of PSUR is provided in this module and also refers to PBRER format as per the ICH-E2C(R2) guideline. 

This is scientific document which compiles the safety data related to the particular medicinal product. Analysis of this safety data in terms of its impact on benefit-risk profile of product. 

Why is it written?

 To determine whether there are new risks or whether risks have changed or whether there are changes to the risk-benefit balance of medicinal products

When is it written?

Usually PSUR is required for new authorized products or products that are launched recently in new indication or formulation etc. Products for whom safety profile is not yet established. With this background, the PSUR is usually not required for generic or OTC products unless requested by agency or NCA.

The timelines are below as per module.

  • within 70 calendar days of the data lock point (day 0) for PSURs covering intervals up to 12 months (including intervals of exactly 12 months); 
  •  within 90 calendar days of the data lock point (day 0) for PSURs covering intervals in excess of 12 months; 
  •  the timeline for the submission of ad hoc PSURs requested by competent authorities will normally be specified in the request, otherwise the ad hoc PSURs should be submitted within 90 calendar days of the data lock point.

How is it written?

The sections along with short expectation for each section is summarized from detailed requirements for each section in module.


Part I: Title page including signature

It should be clear who are the signatories at organizational level. Generally it is head of PV, CMO, Safety physician, medical writer.

 Part II: Executive Summary 

This section should provide summary of product in terms of indication, review period, analysis of data and its impact on benefit-risk assessment, exposure data. The section is used for wider audience (non-PV) so the aim is to keep it concise and clear. 

Part III: Table of Contents (TOC)

As the PSUR is very lengthy documents easy navigation via TOC is mandatory.

Section 1 Introduction

This covers products introduction, review period, patient exposure, disease/indication.

Section 2 Worldwide marketing authorisation status

This is generally presented in tabular format which explains the products status across worlf, IBD, approval country and date.

Section 3 Actions taken in the reporting interval for safety reasons

This includes actions for the product in investigational (clinical trial ) or marketing. The actions alongside reasons should be provided. E.g. Change in RSI (SmPC, USPI), Protocol modifications, suspension, withdrawal, pack size, restriction on use, communication to consumers or HCPs.

Section 4 Changes to reference safety information

Any changes to RSI implemented during the review period i.e. change in warnings, precautions, contraindications etc should be explained.

Section 5 Estimated exposure and use patterns

In this section we use sales data to calculate patient exposure and other data such as from clinical trials. The age group, gender, different usage etc. can also be found from this data for categorization.

Section 6 Data in summary tabulations

This refers to data from safety database. No need to present single ICSR cases, but cumulative assessment. If there are few cases that needs to be described then the narrative should not be copy paste from CIOMS, but clinical assessment of narrative.

Section 7 Summaries of significant findings from clinical trials during the reporting interval

Present the data analysis form each study in terms of new safety information herein. Tabular format of ongoing or completed studies by study ID, indication, age/sex etc can be presented.

Section 8 Findings from non-interventional studies

Aggregate analysis of data and its impact from various non interventional studies such as observational studies, epidemiological studies, registries, and active surveillance programs.

Section 9 Information from other clinical trials and sources

This section should provide pooled aggregate analysis of data from other clinical trials and data on medication errors etc.

Section 10 Non-clinical data

This section will provide analysis and summary of major safety findings from non-clinical in vivo and in vitro studies (e.g. carcinogenicity, reproduction or immunotoxicity studies) ongoing or completed during the reporting interval.

Section 11 Literature

This section will describe the articles that were found to be relevent form the risk-benefit analysis of product.

Section 12 Other periodic reports

If there are other periodic reports developed then summarize finding from that report herein. 

Section 13 Lack of effect

13. This section should summarize data regarding lack of efficacy, or lack of efficacy especially to product's used treat or prevent serious or life-threatening illnesses.

 Section 14 Late breaking information

 This is not per se cases received unless they are index case and promoted as signal. This refers to clinically significant new publications, important follow-up data, clinically relevant toxicological findings and any action that the marketing authorization holder, a data monitoring committee, or a competent authority (worldwide) has taken for safety reasons.

Section 15 Overview of signals: new, ongoing, or closed

This section refers to overview of all signal in review period. The signal can be provided as tabulation as well. New signal and their status. Ongoing signal and if any change in its status or relevance. Closed signals and there outcome is presented.

Section 16 Signal and risk evaluation

This should not be repetition of section 15 but rather interpretation of the data on signals. An clinical analysis of signal and how they relate to current risks. An mapping can be provided for the signals to current risks and how they are presented in current RSI or what are risk minimization measures for this risks.  

Section 17 Benefit evaluation

This provides baseline efficacy data and effectiveness of product in the approved indication or new indication if the data is found such. 

Section 18 Integrated benefit-risk analysis for authorized indications

Summary of benefit risk assessment of the product and conclusion on any planned actions for maintaining the same. How the current benefits and risks are addressed for the product and the data suggests the change or it remains same.

Section 19  Conclusion

  • Summary of the data
  • Changes or no changes to benefits
  • Changes or no changes to risk
  • Integration of risk and benefits
  • Proposed plan on how to balance the BR  e.g. any risk minimization measures

Section 20 Appendices of PSUR

1. RSI

2. ICSR tabulations from safety database

3. Tabular summary of safety signals

4. List of all clinical trials

5. Regional appendices

It is important to note which reference safety is used during PSUR, there are multiple variations given in the module. It is most common to use the RSI that was effective at the end of the review period.

Written by:

Dr.Shraddha Bhange.

Connect with me Via comments below. (I do not respond to Facebook or Linkedin messages actively)

Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home







Written by:

Dr.Shraddha Bhange.
Connect with me Via comments below. (I do not respond to Facebook or Linkedin messages actively)
Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home

Summary of Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products

 Summary of Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products

Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module VI having covered module I , II, III, IV and V in previous blogs.

This module describes the ICSR requirements.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to collect, process, analyze and submit ICSRs.

1. Definitions in ICSR : When we are processing cases, we are confused on requirements, going back to basics and looking at definitions helps. Definitions are provided for Adverse drug reaction, seriousness criteria special case scenario e.g. misuse, abuse, medication error, lack of efficacy etc.

2. Processing of ICSR : The requirements of ICSR processing, including identifying correct source type i.e. solicited, unsolicited. Type of cases and its requirements spontaneous, literature and clinical trials.

3. Submission of ICSR: Submission format, content and timelines are provided.

"The submission of serious valid ICSRs is required as soon as possible, but in no case later than 15 calendar days after initial receipt of the information by the national or regional pharmacovigilance centre of a competent authority or by any personnel of the marketing authorization holder, including medical representatives and contractors. This applies to initial and follow-up information." ICSR can be submitted electronically and follows ICH guidelines.

4. Nullification of ICSR: This is when the case is created erroneously then a follow up will eb submitted notifying EMA and then nullified.

5. Amendment of ICSR: When a previously submitted ICSR has to be corrected (without getting follow up) then amended ICSR should be submitted. The amended fields should impact the meaning of case i.e. seriousness, listedness, company comment, causality etc.

Reference:https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf


Written by:

Dr.Shraddha Bhange.
Connect with me Via comments below. (I do not respond to Facebook or Linkedin messages actively)
Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home


Summary of Module V – Risk management systems

 Module V – Risk management systems 

Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module V having covered module I , II, III and IV  in previous blogs.

This module describes the risk management plan (RMP) requirements, structure and content.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to write, compile, contribute or review RMP.

1. What is RMP?

“The aim of a risk management plan (RMP) is to document the risk management system considered necessary to identify, characterize and minimize a medicinal product’s important risks.”

RMP describes the risk associated with the product, the severity, seriousness, outcome and impact of risk on patient and general population. It also should describe the disease (Indication) and the product details.

2. When is it written?

RMP is written at the time of approval of product, renewal of product and in the time period when the first PSUR following the first 5 year renewal is due for submission. RMP is a living document meaning it needs to be updated as the information's regarding product gets updated. RMP is also updated at the time of PSUR 

3. How is it written?

GVP module describes the template and sections thoroughly . Providing the gist of sections below.

Module I Product Overview- Description related to product

Module II Safety specification- This section refers to identified risk, potential risk and missing information, it also describes the epidemiology, clinical and non clinicals data, patient exposure and risk. The risks need to be described in terms of their severity, seriousness, outcome, treatability and impact on patient and general population.

Module III Pharmacovigilance plan (including post-authorization safety studies): This describes the risk and there status (identified risk if it was potential before), severity, frequency and impact on patients. It describes routine and additional pharmacovigilance activities.

 Module IV Plans for post-authorization efficacy studies:

Module V :Risk minimization measures (including evaluation of the effectiveness of risk minimization activities): This section defines the routine and additional risk minimization measures. E.G. Legal status of products, Smpc, pack size etc

Part VI Summary of the risk management plan:

This section is must and is also published on the EMA website, the audience is broad and hence this section should be well written and explained. It should describe the product and its status, indication, its current risk status (identified, potential and missing information) and the risk minimisation measures currently implemented for same.


4. Why is it written?

Ideally RMP is legal and compliance requirement, but the reasons for writings an RMP is to ensure all the risks are summarized alongside the detailed, clear and concise plan on how to minimize them. This ensures patient safety. Also the risk minimization measures and the plan to monitor those effectiveness then becomes legally binding furthering the cause of patient safety.

In nutshell, a RMP is very detailed scientific document that requires lot of expertise in PV, clinical and medical side of it. This should hence be prioritized to be written with experts that have all this background and also the timelines and effort to complete the document should be strategized very well in advance.


Written by:

Dr.Shraddha Bhange.
Connect with me Via comments below. (I do not respond to Facebook or linkedin messages actively)
Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home



Summary of GVP IV Pharmacovigilance audits

 

Summary of GVP IV Pharmacovigilance audits

Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module IV having covered module I , II and III  in previous blogs.

This module describes the pharmacovigilance audits why are they conducted, what is the goal, who conducts and when are they conducted.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to lead, participate or contribute to an audit themselves. 

An audit is an opportunity for they system owners and individuals to identify how cna we prevent any issue/concerns that could possibly impact the process and may lead to impact on product or patients. It is an opportunity to identify if the systems, tools, process and personnel are effective and as per regulations and industry standard. 


Here is the link https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-iv-pharmacovigilance-audits-rev-1_en.pdf

What is audit?

"An audit is a systematic, disciplined, independent and documented process for obtaining evidence and evaluating the evidence objectively to determine the extent to which the audit criteria are fulfilled, contributing to the improvement of risk management, control and governance processes".

An audit determines the deficiency in the pharmacovigilance system and its supporting tools so that corrective and preventive actions (CAPA) can be implemented.

 When is it conducted?

Audits are conducted based on internal strategy by MAH or agency or NCA. There can be planned audits and for cause audits. The frequency of audit can be determined based on PV systems and requirements. MAH are required to conduct regular audits and also enter major and critical findings along with the CAPA in the PSMF

Who conducts it?
Trained and exert Auditors can only conduct audits. They need to have required skills and trainings. Pharmacovigilance knowledge, skills and abilities as well as Quality standards, knowledge, skills in audit principles, procedures and techniques; and RA applicable laws, regulations as well as processes and systems background; management system and organizational system. 

How?

An audit that should be conducted required planned agenda, strategy, objective, sufficient written documentation of each of this and appropriate time to be given to all the stakeholders involved. Audit will involve looking at SOP, Process, interview the personnel, training records etc. An official audit report with written documented findings i.e. critical, major and minor will be released to the owner of PV system.

The owner of the system and process i.e. department heads will then have to populate written responses to each findings with CAPA and timelines.


Written by:

Dr.shraddha Bhange.
Connect with me Via comments below. (I do not respond to Facebook messages)
Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home

Summary of GVP III Pharmacovigilance inspections

 (GVP) Module III – Pharmacovigilance inspections


Continuing the series on Guideline on good pharmacovigilance practices, in this blog i will jump right into module III having covered module I and II  in previous blog.

This module describes the pharmacovigilance inspections, why are they conducted, what is the goal, who conducts and when are they conducted.

Overall, the module does go in more and clear details on expectations and its best to read module thoroughly and completely when one has to lead, participate or contribute to an inspection themselves. 


Here is the link: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections_en.pdf

1. What is inspection ?

An inspection is done by national competent authority (NCA) or EMA agency of MAHs systems, processes and personnel to ensure they are fulfilling all legal obligations required to ensure risk benefit monitoring of product authorized in EU for safeguarding patient safety. 

2. When are inspections conducted?

1. Routine inspections : This are conducted routinely as per agency's risk monitoring based approach.

2. For cause inspections : This inspections are conducted when agency or NCA is inspecting any non compliance or failure of MAH to fulfill any PV obligations.

"As a general approach, a marketing authorization holder should be inspected on the basis of risk-based considerations, but at least once every 4 years"

Interesting examples given in module are below:

2. 1. Risk benefit balance

When MAH fails to inform about withdrawal or suspension of product

Any change in risk benefit was not communicated properly 

2.2. PV obligations

 Not submitting ICSR, PSUR or any other documents with quality and on time

2.3. Failure to respond to NCA/Agency requests

Not responding with adequate data and/or correct data at correct time

3. Who conducts inspections?

Inspector appointed and approved by agency and/or NCA.

4. Types of inspections: 

4. 1. Routine inspections : Conducted routinely as part of risk based approach at agencies end.

4. 2. For cause inspections as noted above some of the causes.

4. 3. Pre authorization inspections : This inspections are conducted for MAH who are applying for first time authorization in EU and Agency/NCA wants to ensure MAH has robust, efficient PV process

4. 4 Post authorization inspections: This inspections are conducted as follow up to preauthorisation once the approval is granted to ensure the MAH is legally compliant and also has all the required process and systems in place

4.5 Announced and unannounced inspection- as the name suggests some inspection are preplanned and informed with agenda and details to MAH i.e. announced and some are unannounced when the agency/NCA has reasons to conduct the same

Other types are follow up, remote, system specific, product specific inspections.

5. Common process or systems that are inspected

1. ICSR- Death and SUSAR cases are picked up

2. Products- those that have been recently approved or have been identified with new signals/risks or safety concerns

3. Aggregate reports - PSUR for products that was delayed, inadequate or has inconsistent data 

4. Signal or risk management : Signal process overall especially documentation of any downgraded or closed/invalid signals and for risks that have been recently identified and for which there are minimization measures in place

5. Products or clinical studies that are closed and have been used as basis for approval . Any study for which GCP inspection flagged an issue.

Ideally, the more detailed module should be referenced to know more about inspection planning, reasons, outcomes and expectations. 

6. Outcome of inspections:

A MAH will be required to provide and responds with documented evidence to agency/NCA for every inspection observation, minor or major findings with stipulated timelines for every corrective or preventive actions. An agency or NCA may take action on MAH based on this which maybe - warning, withdrawal, suspension, conditional approval etc.


Written by:

Dr.shraddha Bhange.
Connect with me Via comments below. (I do not respond to Facebook messages)
Support the cause of better rural education with me:ThinkSharp Foundation http://thinksharpfoundation.org/#home

Disclaimer

Disclaimer